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In vivo demonstration of an active tumor
pretargeting approach with peptide nucleic acid
bioconjugates as complementary system†
Anna Leonidova,‡a Christian Foerster,‡§b Kristof Zarschler,b Maik Schubert,b
Hans-Jürgen Pietzsch,b Jörg Steinbach,b Ralf Bergmann,b Nils Metzler-Nolte,c
Holger Stephan*b and Gilles Gasser*a
A novel, promising strategy for cancer diagnosis and therapy is the use of a pretargeting approach. For this
purpose, the non-natural DNA/RNA analogues Peptide Nucleic Acids (PNAs) are ideal candidates as in vivo
recognition units due to their high metabolic stability and lack of unspecific accumulation. In the
pretargeting approach, an unlabeled, highly specific antibody–PNA conjugate has sufficient time to
target a tumor before administration of a small fast-clearing radiolabeled complementary PNA that
hybridizes with the antibody–PNA conjugate at the tumor site. Herein, we report the first successful
application of this multistep process using a PNA-modified epidermal growth factor receptor (EGFR)
specific antibody (cetuximab) and a complementary 99mTc-labeled PNA. In vivo studies on tumor bearing
mice demonstrated a rapid and efficient in vivo hybridization of the radiolabeled PNA with the antibody–
PNA conjugate. Decisively, a high specific tumor accumulation was observed with a tumor-to-muscle
ratio of >8, resulting in a clear visualization of the tumor by single photon emission computed
tomography (SPECT).
Introduction
The excellent target specicity of monoclonal antibodies (mAbs)
renders this class of biomacromolecules a benecial platform to
detect and treat tumor malignancies. In nuclear medicine, such
tumor antigen-specic vehicles labeled with radionuclides
would be applicable for non-invasive imaging of diseases and
more importantly, for in vivo delivery of therapeutically relevant
radioactivity doses to tumor sites. Unfortunately, the concept of
utilizing radionuclide-carrying tumor-specic mAbs is afflicted
with several drawbacks,1–3 mainly arising from the high
molecular weight of mAbs (150 kDa). Due to size-related
limitations in passing biological barriers,4 such as extravasation
and the inability of glomerular ltration, mAbs exhibit a slow
but gradual accumulation in tumor sites and long blood
retention times of up to several days, respectively.5 The slow
blood clearance rate of mAbs forces extensive waiting times
before acquiring a diagnostic image with reasonable signal-to-
background ratio as well as to label with appropriate isotopes.6,7
Detrimental radiation exposure for almost all tissues in the
organism, especially during therapeutic applications, will be
the result of their prolonged blood pool retention time.8 Despite
innumerable research activities and efforts conducted so far,
only two drugs, namely Bexxar® and Zevalin™, representing
radiolabeled mAbs for treatment of Non-Hodgkin's lymphoma
are currently approved by the FDA.9–11
An attractive strategy to circumvent these limitations is the
use of a pretargeting approach that involves an articial in vivo
recognition system composed of a nonradioactive antibody
conjugate and a small radiolabeled “effector” molecule. As
schematically represented in Scheme 1, in this multistep
process, an unlabeled, highly tumor-specic antibody conjugate
is rst administrated into a patient. Upon injection, sufficient
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time is allowed for the antibody conjugate to reach the tumor
and to be eliminated from the non targeted tissues. This is then
followed by the administration of a small fast-clearing radio-
labeled “effector”molecule that binds to the antibody conjugate
at the tumor site.12,13 This approach allows for the rational use of
long-circulating high-affinity mAbs for both non-invasive cancer
radioimmunodetection and radioimmunotherapy.14,15
Several recognition systems have been investigated and to
some extend clinically tested for different pretargeting
approaches. Most prominent among them are streptavidin/
biotin,16–19 bispecic antibody/hapten20–27 and synthetic
complementary oligonucleotides/oligonucleotides such as
morpholino and peptide nucleic acid derivatives.28–34 For more
detailed information and secondary references, we highly
recommend the review article of Goldenberg et al.35 Beside the
“classical” recognition by supramolecular motifs, bio-orthog-
onal and ultra-fast click reactions have also been developed as
complementary system in vivo.36–39
Among the range of synthetic oligonucleotides investigated
for pretargeting, phosphorodiamidate morpholino oligomers
(MORFs) and Peptide Nucleic Acids (PNAs, Scheme 1) have
emerged as promising candidates. Both derivatives are non-
charged mimics of the naturally occurring ribonucleic acids
DNA and RNA. They exhibit a suitable degree of water solubility,
are almost inert towards degradation in vivo,40,41 and insensitive
towards chemical modications even under harsh conditions.
The superior intrinsic properties of PNAs over DNA/RNA have
made them extremely interesting candidates for applications in
(nuclear) medicine or biology. Radiolabeled PNA oligomers
were indeed utilized as probes for molecular imaging of target
specic mRNA sequences.42–48 However, the relatively low
cellular uptake of PNAs has represented a serious drawback,
which has undoubtedly delayed their use as antisense or
antigen agents, although several techniques are now available
to overcome this problem (e.g. use of cell-penetrating peptides,
etc.). Nonetheless, the limited cellular uptake of PNAs creates a
very interesting bio-orthogonal system. Indeed, administration
of a radiolabeled PNA strand into a living organism rarely
results into unspecic binding.34,48 In other words, the PNA
strand is usually excreted in its intact form from the kidney/
liver. This characteristic, in addition to the excellent physico-
chemical properties discussed above, have made PNAs a
promising tool in the tumor pretargeting approach.
Pioneering work in this eld of research was performed by
Hnatowich and co-workers, who demonstrated a rst proof-of-
concept in 1997.32–34,49 In those studies, surrogates such as PNA-
loaded polymeric32,34 and agarose-based avidin beads49 trans-
planted into mouse thighs were used. To the best of our
knowledge, there is only a single report describing the utiliza-
tion of PNA–streptavidin bioconjugates for (non-specic) tumor
localization in a mouse model by passive diffusion.33 These
PNA–protein conjugates were found to accumulate unspeci-
cally in most tissues of the animals. Consequently, upon
administration of the radiolabeled complementary PNA,
radioactivity levels were signicantly higher compared to
control animals. However, tumor antigens have not been
specically targeted by anti-tumor antibody–PNA conjugates
yet. Thus, a critical evaluation of a tumor pretargeting concept
in vivo is still lacking.
In this work, we aim to demonstrate the suitability of
PNA-based bioconjugates as versatile complementary system
for the specic transportation and accumulation of radionu-
clides in tumors. More specically, in this article, we rst
describe the preparation and characterization of several PNA
bioconjugates that contained different building blocks such as
a 2,20-dipicolylamine (Dpa) to chelate the radioactive 99mTc as
well as polyethylene glycol (PEG) units to tune the bio-
distribution of the PNA oligomers. In addition, radiolabeling of
the Dpa-containing bioconjugates with [99mTc]Tc(H2O)3(CO)3
+
as well as detailed radiopharmaceutical evaluation including
biodistribution and metabolic proling is presented.
Of note, to critically assess the PNA-based pretargeting
system used in this work, the well-studied, FDA-approved
therapeutic mAb cetuximab (C225; Erbitux®, ImClone LLC) was
selected, since it is commercially available and shows chemical
robustness as well as a high affinity to a clinically relevant
tumor biomarker.50–54 The molecular target of cetuximab,
namely the epidermal growth factor receptor (EGFR),55,56 is
involved in regulating cell growth, differentiation and survival
of cells.57,58 In a variety of human malignancies, EGFR is
constitutively activated as a result of receptor overexpression,
mutation or deregulation59–61 and has therefore been investi-
gated as a major target for the treatment of uncontrolled tumor
growth.62–64 All in all, this article demonstrates, for the rst time,
the successful tumor pretargeting approach using radiolabeled
PNAs in combination with PNA–antibody bioconjugates in
murine xenogras (human squamous carcinoma cell line
A431). This report highlights the immense potential of this
approach for both cancer radioimmunodetection as well as
radioimmunotherapy.
Results and discussion
Synthesis and characterization of PNA bioconjugates
All PNA oligomers and bioconjugates were synthesized manu-
ally on TentaGel S Fmoc-Lys(Boc)-RAM resin using commer-
cially available Fmoc/Bhoc-protected PNA monomers and
standard protocols previously reported by our groups.65 For
sufficient stability of PNA–PNA hybrids, complementary PNA
oligomers consisting of 17 bases were designed. Table 1
summarizes the PNA sequences used in this work. In order to
radiolabel PNA with [99mTc]Tc(H2O)3(CO)3
+, 2,20-dipicolylamine
(Dpa) was site-specically introduced by copper-mediated 1,3-
dipolar cycloaddition (“Click” Chemistry) as previously reported
by our groups.66 In order to improve the pharmacokinetics and
bioavailability of compounds and drug carriers, we envisaged
PEGylating the PNA bioconjugates as described in the literature
for different biomolecules.67–73 However, in the different studies
having investigated the use of PEG-containing PNAs oligomers,
the full impact of PEGylation on PNA's pharmacokinetics and
biodistribution was not assessed.65,74–82
Of note, some of us recently demonstrated that PEGylation of
17-mer L-congured DNA-oligonucleotides – another promising
complementary system – signicantly altered
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radiopharmacokinetics. Indeed, a non-specic accumulations
in kidneys was markedly reduced by 90%, while the blood
circulation half-life was strongly increased by factor of 4.83 More
specically, in this work, two different PNA bioconjugates,
namely Dpa-PNA and Dpa-Cys-PNA (Entries 1 and 2 in Table 1),
were rst synthesized as radionuclide carriers. Maleimido-PEG
derivatives (2 and 10 kDa) were then inserted via Michael-type
addition into the cysteine-containing PNA Dpa-Cys-PNA to give
Dpa-(Cys-PEG2kDa)-PNA and Dpa-(Cys-PEG10kDa)-PNA, respec-
tively (Entries 4 and 5 in Table 1). For this purpose, pretreatment
Scheme 1 General principle of tumor pretargeting using Peptide Nucleic Acids (PNA). Firstly, unlabeled, highly specific antibody–PNA conju-
gates are administered intravenously into the patient (A). After accumulation of the antibody conjugates at the tumor site and clearance from
non-target tissues, small fast-clearing radiolabeled complementary PNAs are injected (B), that hybridize with antibody–PNA conjugates (C). The
radioactivity symbols inserted into the 2,20-dipicolylamine (Dpa) chelator illustrate either 99mTc(CO)3 or
186Re(CO)3, which are used for diagnosis
or therapy, respectively (D). While DNA has a deoxyribose sugar backbone, the PNA's backbone is composed of repeating N-(2-aminoethyl)-
glycine units linked by amide bonds. Their various purine and pyrimidine bases are linked to the backbone by a methylene bridge and a carbonyl
group (E).
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5601–5616 | 5603






















































































































of Dpa-Cys-PNA with the strong reducing agent tris(2-carbox-
yethyl)phosphine (TCEP) was found to be necessary to improve
the yields of conjugation reaction by preventing PNA–PNA
disulde dimer formation.74,80 Prior to the addition of mal-
eimido-PEG derivatives, excessive TCEP was removed by size
exclusion chromatography to avoid reduction of C–C double
bond of maleimide entity leading to sulydryl-unreactive succi-
nimide derivatives. In addition, a cysteine-containing PNA olig-
omer, Cys-c-PNA (Entry 3 in Table 1), which is complementary to
the other PNA sequences of this study, was prepared. The identity
of all PNA analogues Dpa-PNA, Dpa-Cys-PNA, Cys-c-PNA, Dpa-
(Cys-PEG2kDa)-PNA, and Dpa-(Cys-PEG10kDa)-PNA was conrmed
by ESI-MS and MALDI-TOF MS. The high purity of the bio-
conjugates was veried by LC-MS (Fig. S2, S5, S8, S10 and S12†).
Apart from the [M + nH]n+ peaks, additional [M + Cu + nH]n+, [M
picolyl + Cu + nH]n+ were also observed in both ESI and MALDI-
TOF spectra for Dpa-containing products. This effect is due to the
traces of copper ions still present aer the introduction of Dpa to
PNA sequence by “Click” Chemistry. Due to the polydispersity of
PEG polymers combined with the multiple charged conjugates,
ESI-MS generated spectra with multitudinous m/z peaks
disabling conclusive results. The presence of Dpa-(Cys-PEG2kDa)-
PNA and Dpa-(Cys-PEG10kDa)-PNA was, however, unambiguously
conrmed by MALDI-TOF, where only single and double positive
charged species were observed (Fig. S11, S13†).
Hybridization properties
In order to assess self-complementary interactions between the
PNA strands, we performed UV-based melting curves for each
single stranded PNA oligomers, namely Cys-c-PNA, Dpa-PNA,
Dpa-(Cys-PEG2kDa)-PNA and Dpa-(Cys-PEG10kDa)-PNA. As dis-
played in Fig. S16†, no homo-hybridization was observed. In the
case of hetero-hybridization, our data listed in Table S1† show
that, even at room temperature, Cys-c-PNA forms perfect
hybrids with all other PNA derivatives (complete match). The
determined melting temperatures were almost independent of
the degree of PEGylation.
Bioconjugation between Cys-c-PNA and cetuximab
Cetuximab (C225; Erbitux®, ImClone LLC), a chimeric human-
murine IgG1 monoclonal antibody, binds specically to the
extracellular domain of the epidermal growth factor receptor
(EGFR) on both normal and tumor cells, and competitively
inhibits the binding of epidermal growth factor (EGF) as well as
other ligands. EGFR is oen overexpressed in human malig-
nancies and is associated with poor clinical prognosis.84,85
Cetuximab binding to EGFR blocks phosphorylation. This
blockage results in inhibition of downstream cellular processes
such as induction of apoptosis and cell growth. Due to its
promising antitumor activity, cetuximab has been approved for
the treatment of colorectal and head and neck squamous cell
carcinoma as well as with external radiotherapy for the treat-
ment of head and neck squamous cell carcinoma.86 Of note, we
have recently shown that cetuximab labeled with the thera-
peutic b-emitter 90Y could improve permanent local tumor
control aer external radiotherapy.52 Since this well-studied
anti-EGFR antibody possesses a high affinity to its molecular
target, shows chemical robustness and is commercially avail-
able, we selected it as model for radiopharmaceutical evaluation
of our PNA-based pretargeting system.
Prior to attachment of Cys-c-PNA to cetuximab, the anti-
EGFR antibody was modied with 1,4,7-triazacyclononane-
1,4,7-triacetic acid (NOTA),87 a suitable [64Cu]Cu2+ chelator for
PET-monitoring of aspired PNA–cetuximab bioconjugate.88–91
This allows us to quantify such important parameters as blood
circulation half-life and tumor accumulation of PNA–cetuximab
and therefore to optimize the administration regime of PNA–
cetuximab conjugate and radiolabeled PNA. NOTA was
successfully conjugated to cetuximab resulting in an average of
three NOTA molecules per antibody to give (NOTA)3-C225.
Subsequent introduction of a maleimido group to (NOTA)3-
C225 was successfully performed by reaction of (NOTA)3-C225
with 4-maleimido-butyric acid N-succinimidyl ester (GMBS) to
obtain (NOTA)3-C225-mal.
Finally, Cys-c-PNA was linked to (NOTA)3-C225-mal under
mild reaction conditions to give the bioconjugate (NOTA)3-
C225–Cys-c-PNA (Entry 6 in Table 1). The average number of
conjugated Cys-c-PNA to (NOTA)3-C225-mal was quantied by
determination of the absorbance ratio 260 nm/280 nm in the UV
spectrum.92–94 Based on this method, 2.2  0.7 Cys-c-PNA
moieties per antibody were found. MALDI-TOF MS analysis
conrmed this result since the determined number of
2.4 bound PNA oligomers per antibody is in the same range as
calculated by UV method (see Fig. S14†).
Radiochemistry
99mTc-radiolabeling of Dpa-PNA, Dpa-(Cys-PEG2kDa)-PNA and
Dpa-(Cys-PEG10kDa)-PNA was performed via the precursor








a Spacer ¼ –NH(CH2)2O(CH2)2OCH2CO–.
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+ generated by the IsoLink® kit “Carbonyl
Labeling Agent”.95 Highly concentrated [99mTc(H2O)3(CO)3]
+
precursor with radiochemical yields (rcy) of >95% was obtained
by concentrating the solution at 100 C for 30 min. Up to
580MBq of 99mTc precursor was added to 10 nmol of each of the
Dpa-bearing PNA conjugates to give the corresponding radio-
labeled PNA conjugates with rcy >95% and high effective
specic activities of up to 58 GBq mmol1 (n ¼ 19). Detailed
studies to improve radiolabeling conditions have shown a
strong dependency of rcy on the pH of the radiolabeling
mixture. Radiolabeling at pH < 7 resulted in incomplete
complexation of [99mTc(CO)3]
+ with rcy of <85%, while the rcy
went to up to >95% at optimized conditions (70 C, 40 min,
10 nmol of PNA conjugate) when pH in the range from 7 to 8 was
applied.
Aer purication of 99mTc-labeled PNA derivatives by HPLC,
partition experiments were performed in 1-octanol/buffer
systems to assess the lipophilicity/hydrophobicity of the radio-
labeled PNAs. Distribution ratio log Do/w was determined at
three different pH values (Table 2). Surprisingly, the log D
values were almost independent on the degree of PEGylation
within the tested pH range (7.2–7.6). Compared with previously
published results based on a 12-mer PNA conjugate,48 it appears
that the hydrophilicity is increased more by the lengthening of
the PNA chain from 12-mer to 17-mer, rather than by the
PEGylation.
In order to examine if the modication of cetuximab with
Cys-c-PNA resulted in loss of affinity to the EGFR, the antibody
derivatives (NOTA)3-C225 and (NOTA)3-C225-Cys-c-PNA were
radiolabeled with [64Cu]CuCl2. Of note, the pH of the [
64Cu]
CuCl2 labeling solution had to be adjusted to around 6 prior
addition to the solutions containing the cetuximab conjugates
to avoid antibody denaturation. In addition, due to the sensi-
tivity of the antibody, mild reaction conditions (30 C without
shaking) were used. (NOTA)3-C225 and (NOTA)3-C225-Cys-c-
PNA were labeled with effective specic activities of up to
16.7 GBq mmol1 and radiochemical yields >99%.
Affinity of [64Cu]Cu-(NOTA)3-C225-Cys-c-PNA and [
64Cu]Cu-
(NOTA)3-C225 to the EGFR
In order to evaluate the inuence of PNA-conjugation on the
antibody's binding specicity and affinity to human EGFR, the
dissociation characteristics of [64Cu]Cu-(NOTA)3-C225-Cys-c-
PNA and [64Cu]Cu-(NOTA)3-C225 were determined compara-
tively using two dimensional cell cultures of epidermoid
carcinoma (A431) and squamous carcinoma (FaDu) cells. These
tumor cell lines present different expression levels of the
receptor on their cell surface.96
Fig. 1 shows the saturation binding curves of radiolabeled
cetuximab conjugates for both cell lines. For [64Cu]Cu-(NOTA)3-
C225-Cys-c-PNA and [64Cu]Cu-(NOTA)3-C225, Scatchard anal-
ysis was applied to determine dissociation constants (Table 3). A
Kd of 5.4  0.9 nM and Bmax of 13.3 pmol per mg protein for
A431 and a Kd of 1.1  0.2 nM and Bmax of 1.9 pmol per mg
protein for FaDu cells were obtained for [64Cu]Cu-(NOTA)3-
C225-Cys-c-PNA. [64Cu]Cu-(NOTA)3-C225 showed slightly
different dissociation constants with a Kd of 7.7  0.8 nM and
Bmax of 15.9 pmol per mg protein for A431 and a Kd of 2.0 
0.3 nM and Bmax of 2.9 pmol per mg protein for FaDu cells.
Modication of the monoclonal antibody with PNAs does not
affect its binding behavior to EGFR expressing tumor cells. This
is of particular importance since the immunoreactivity as well











7.2 0.86 (2.35  0.04) (2.28  0.07) (2.40  0.02)
7.4 0.85 (2.22  0.03) (2.20  0.02) (2.22  0.04)
7.6 0.84 (2.35  0.07) (2.42  0.06) (2.35  0.02)
a Shown are the averages of three independent experiments with the standard deviation in parentheses.
Fig. 1 In vitro binding studies of radiolabeled cetuximab conjugates.
Saturation curves of [64Cu]Cu-(NOTA)3-C225-Cys-c-PNA and [
64Cu]
Cu-(NOTA)3-C225 upon incubation with human EGFR-positive tumor
cell lines A431 (A) and FaDu (B).
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5601–5616 | 5605






















































































































as the high affinity of cetuximab to EGFR has to be conserved
aer chemical conjugation.56
The variation in the affinity of the antibody conjugates
between A431 and FaDu cells can be explained by the different
cellular context. Such an effect has been previously reported for
EGF.97 Björkelund and co-workers indeed observed an impor-
tant inuence of the investigated cell lines on the binding
characteristics and on the multiple ligand–receptor interac-
tions. The authors explained these phenomena by the occur-
rence of varying ratios of EGFR homodimers and heterodimers
composed of EGFR and the human epidermal growth factor
receptor 2 (HER2) due to different expression levels of these
receptors. The different ratios of EGFR and HER2 may also
account for the herein described variation in the affinity of the
cetuximab conjugates between A431 and FaDu cells. The former
cell line overexpresses EGFR with 1–3  106 receptors per cell98
and has a lower HER2 expression,96,99,100 whereas the latter cell
line possesses a large HER2 population and presents less EGFR
on the cell surface (7  105 receptors per cell).96,99,101
Biodistribution studies
The data previously presented by Hnatowich and co-
workers32–34,49 and by our laboratories48 demonstrated favorable
properties of radiolabeled PNAs towards in vivo tumor pre-
targeting applications. These include very fast distribution, low
non-specic accumulation in non-targeted tissue as well as
renal elimination as preferred elimination pathway from
organism. However, these experiments also showed that
specic accumulation of radiolabeled PNA derivatives in pre-
targeted tumor tissue might not be sufficiently high for thera-
peutic approaches.33,34,49 The reason behind it is certainly the
rapid elimination of the radiolabeled PNA from blood. The
major aim of attaching large PEGmoieties onto our 17-mer PNA
oligomers was therefore to increase blood retention and
subsequently enhance blood availability. This should result into
increased hybridization incidences in pretargeted tumor tissue.
As an initial step of this evaluation process, we determined
the impact of the degree of PEGylation on the radio-
pharmacological behavior by conducting biodistribution
studies and dynamic SPECT scans in healthy male Wistar rats.
To ensure comparability and compatibility with further animal
studies as well as published results, the data presented are the
means  standard deviation of standard uptake values (SUV),
dened as the tracer concentration at a certain time point
normalized to injected dose per unit body weight. Detailed
biodistribution data presented as SUV and %ID are summa-
rized in Tables S2 and S3.† At 5 min post injection (Table 4), the
99mTc-labeled 17-mer PNA conjugates clearly showed an
elevated level of activity concentration in the blood pool with
increasing degree of PEGylation. Compared to the non-PEGy-
lated 17-mer Dpa-PNA, the attachment of PEG led to about 10%
and 45% higher activity concentration in the blood pool for
2 kDa PEG and 10 kDa PEG, respectively.
In agreement with the concept of tumor pretargeting,102 all
radiolabeled PNA conjugates were distributed by the blood
stream very rapidly and were almost completely eliminated
from the blood pool 60 min aer administration. This
Table 3 In vitro binding characteristics of radiolabeled cetuximab






A431 Kd 5.4  0.9 nM 7.7  0.8 nM
Bmax 13.3  0.6 pmol mg
1 15.9  0.4 pmol mg1
FaDu Kd 1.1  0.2 nM 2.0  0.3 nM
Bmax 1.9  0.1 pmol mg
1 2.9  0.1 pmol mg1
Table 4 Biodistribution data for 99mTc-labeled PNA derivatives performed in healthy male Wistar rats at 5 min and 60 min after single intra-


















Blood 1.36  0.21 0.24  0.10 1.51  0.13 0.24  0.06 2.01  0.38 0.34  0.11
Kidneys 11.7  1.60 13.1  1.99 12.0  1.42 9.29  1.10 11.3  1.86 9.75  2.64
Adrenals 0.56  0.12 0.14  0.04 0.80  0.25 0.32  0.21 0.82  0.15 0.25  0.08
Liver 0.91  0.23 0.85  0.26 1.12  0.42 0.98  0.42 1.15  0.21 0.73  0.30
Spleen 0.59  0.31 0.22  0.04 0.92  0.29 0.71  0.34 0.60  0.13 0.54  0.46
Pancreas 0.51  0.30 0.14  0.16 0.35  0.04 0.26  0.25 0.51  0.06 0.61  1.24
Thymus 0.46  0.09 0.10  0.02 0.46  0.08 0.10  0.01 0.45  0.06 0.12  0.04
Muscles 0.38  0.16 0.05  0.01 0.35  0.03 0.09  0.04 0.30  0.08 0.13  0.09
Lung 1.06  0.18 0.22  0.06 2.30  0.69 2.16  1.36 1.41  0.24 0.42  0.16
Heart 0.58  0.07 0.10  0.04 0.64  0.06 0.13  0.04 0.81  0.21 0.17  0.06
Femur 0.56  0.03 0.16  0.02 0.45  0.01 0.14  0.03 0.51  0.07 0.16  0.04
Testicles 0.25  0.13 0.09  0.02 0.34  0.14 0.13  0.03 0.34  0.08 0.16  0.03
Hadrian glands 0.57  0.08 0.12  0.03 0.58  0.18 0.18  0.15 0.59  0.09 0.17  0.04
Brain 0.04  0.01 0.01  0.00 0.04  0.00 0.02  0.02 0.07  0.02 0.01  0.01
Hair & Skin 0.79  0.07 0.24  0.11 0.93  0.08 0.24  0.03 0.86  0.19 0.28  0.07
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minimizes unpredictable whole-body radiation exposure. As
expected for compounds with molecular weights signicantly
lower than 30 kDa and of highly hydrophilic nature (see log Do/w
values from Table 2), the activity was almost exclusively elimi-
nated via the renal pathway.
Compared with previously published results on a 12-mer
PNA conjugate [99mTc](Tc-Dpa-PNA),48 the expansion to a
17-mer conjugate enhanced blood availability 5 min p.i. by
about 12% (Table 5).
In combination with the attachment of a PEG moiety, we
were able to further elevate blood availability to 25% and 66%
for 2 kDa PEG and 10 kDa PEG, respectively. The increase in
the length of the PNA sequence from 12-mer to 17-mer also led
to higher kidney uptake from (7.12  0.43) SUV to (11.71 
1.60) SUV and (5.45  0.45) SUV to (13.11  1.99) SUV 5 min
and 60 min post injection, respectively. Similar relationship
between the length of oligonucleotide sequence and kidney
retention has been reported for morpholino-type oligonucle-
otides92 and has also been observed, in a much greater
extent, for L-congured DNA-oligonucleotides in our
laboratories.83
Based on compiled data (see Fig. 2), among the 17-mer PNA
conjugates used in this study, [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-
PNA exhibits the highest activity concentration in the blood
pool and the lowest activity concentration in liver and kidney
tissue (60 min p.i.) combined with a trend of wash-out from
those organs. This promising 17-mer PNA conjugate was
therefore further evaluated by dynamic SPECT scans.
SPECT image 5 min post injection (Fig. 3) substantiated an
almost homogeneous blood distribution with enhanced activity
concentration in heart, le and right carotids, both kidneys
with hotspots at the renal pelvis, and bladder (urine). As
demonstrated with the SPECT images at 60 min post injection,
the majority of activity has been eliminated from blood pool via
kidneys into the bladder. The calculated activity-under-curve
(AUC) projection clearly shows removal of activity by renal
pathway.
Table 5 Comparison of 99mTc activity concentration of radiolabeled 17-mer PNA conjugates of current studies with previously published 12-mer
PNA48 in healthy male Wistar rats at 5 min and 60 min after single intravenous injection. Data are presented as SUV
12-mer [99mTc]-(Tc-Dpa)-PNA





Blood 5 min p.i.
(60 min p.i.)
1.21  0.05 (0.26  0.10) 1.36  0.21 (0.24  0.10) 1.51  0.13 (0.24  0.06) 2.01  0.38 (0.34  0.11)
Kidneys 5 min p.i.
(60 min p.i.)
7.12  0.43 (5.45  0.45) 11.7  1.60 (13.11  1.99) 12.0  1.42 (9.29  1.10) 11.3  1.86 (9.75  2.64)
Liver 5 min p.i.
(60 min p.i.)
0.99  0.03 (0.67  0.10) 0.91  0.23 (0.85  0.26) 1.12  0.42 (0.98  0.42) 1.15  0.21 (0.73  0.30)
Fig. 2 Comparison of activity concentration (SUV) in the blood,
kidneys and liver of rats after single intravenous injection following
sacrifice at 5 and 60 min p.i.
Fig. 3 Maximum intensity projections generated from dynamic SPECT
(A and B) and calculated activity-under-curve for bladder and kidney
tissue of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA (C) after single intra-
venous administration in single healthy male Wistar rat (SPECT/CT
images and tumor mouse are presented in Fig. S18†).
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Radio-HPLC analysis of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA
samples from rat arterial blood, kidney extracts and urine
showed no metabolic degradation over a time period of 120 min
post injection (Fig. S17†).
Evaluation of the pretargeting approach
These promising radiopharmaceutical results strongly encour-
aged us to investigate the tumor pretargeting approach using
Dpa-(Cys-PEG10kDa)-PNA. Tumor xenogras (epidermoid carci-
noma) were obtained aer subcutaneous injection of A431 cells
into the right thigh of female NMRI nu/nu mice. Imaging and
biodistribution studies were performed when the tumor were in
the range of 8 to 13 mm.
The control experiment in this xenogra model without
pretreatment of (NOTA)3-C225-Cys-c-PNA before injection of
[99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA showed no radioactivity
localization in tumor site (Fig. 4A). The remaining radioactivity
aer 1 h p.i. is mainly located in the kidneys as expected on the
basis of biodistribution experiments with rats described above.
When mice were pretreated with (NOTA)3-C225-Cys-c-PNA
24 h prior to administration of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-
PNA, SPECT images clearly demonstrated an accumulation of
radioactivity at tumor site referring to efficient and rapid in vivo
hybridization at pretargeted tumor tissue. The tumor is clearly
visible aer 60 min (Fig. 4B) and the radioactivity can be
detected for at least 1 day (Fig. 4C). The enhanced radioactivity
level in the kidneys, liver and blood compared to the control
experiment is due to the circulating antibody conjugate. The
activity wash-out from blood and tissues is faster relative to the
tumor. Altogether, the tumor pretargeting using PNA allows for
fast tumor localization and can be considered for improved in
vivo targeting.
For more detailed evaluation of our pretargeting approach,
we also conducted biodistribution studies in eight murine
xenogras, applying the same experimental conditions as
described for SPECT imaging (single intravenous injection of
(NOTA)3-C225-Cys-c-PNA 24 h prior to administration of
[99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA). 24 h post injection of
[99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA, an enhanced radioactivity
concentration of SUV 0.63  0.27 was determined in tumor
tissue (Fig. 5). Compared with non-targeted muscle tissue, a
high contrast of tumor-to-muscle ratio of 8.29  1.28 was ach-
ieved. The elevated levels of activity concentration in blood,
liver, heart, and lung may be explained by incomplete blood
elimination of (NOTA)3-C225-Cys-c-PNA. It is very likely that
circulating (NOTA)3-C225-Cys-c-PNA formed hybrids with
[99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA in blood pool leading to
enhanced retention time of activity in blood and aforemen-
tioned organs. This is in agreements with ndings for PNA–
streptavidin conjugates circulating in the blood to be able to
efficiently bound radiolabeled complementary PNA.33
Although a distinct accumulation of activity in the tumor site
was observed 60 min aer the administration of radiolabeled
complementary PNAs to pretargeted mice, the resulting tumor-
to-blood ratios might not be ideal. We determined that the
waiting period of 24 h between both administrations
represented the optimal balance in terms of rate of blood
clearance and rate of internalization of PNA–cetuximab conju-
gates. On one hand, extended intervals such as 72 h would
enhance blood clearance of the antibody–PNA conjugates as
well as decrease activity concentration in blood, liver, heart, and
lung. On the other hand, PNA–cetuximab conjugates bound to
EGF-receptors are undergoing internalization via receptor-
mediated endocytosis, which gradually diminishes the amount
of hybridization events with radiolabeled complementary PNAs.
For this reason, we believe that extended waiting will not
signicantly enhance tumor-to-background ratios.
Fig. 4 SPECT/CTmaximum intensity projection images of [99mTc](Tc-
Dpa)-(Cys-PEG10kDa)-PNA in murine A431 tumor xenograft (NMRI nu/
nu mice; tumor located at right thigh). (A) 1 h post injection of
[99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA without preinjection of (NOTA)
3-C225-Cys-c-PNA. (B) 1 h post injection of radiotracer; (NOTA)3-
C225-Cys-c-PNA was administered 24 h before injection of radio-
tracer. (C) 20 h post injection of radiotracer; (NOTA)3-C225-Cys-c-
PNA was administered 24 h before injection of radiotracer.
5608 | Chem. Sci., 2015, 6, 5601–5616 This journal is © The Royal Society of Chemistry 2015























































































































The search for novel radiotheragnostic modalities for the
detection and treatment of cancer is currently attracting a lot of
attention worldwide. Among the different options investigated,
the use of a pretargeting approach with the non-natural DNA/
RNA analogues Peptide Nucleic Acids (PNAs) as recognition
units is extremely attractive.33 By temporally separated admin-
istration of the antibody–PNA conjugate and its radiolabeled
complementary PNA counterpart, the important limitations of
conventional directly radiolabeled antibodies are overcome.
Among these limitations, slow blood clearance has been iden-
tied as a major hurdle for diagnostic tumor discrimination,
requiring extensive waiting times, which can last up to a week
aer administration before image acquisition. Furthermore,
mAb accumulation in non-target tissues results in radiation
damage to non-tumor cells and subsequently in severe toxicity.8
The herein exemplied pretargeting approach using PNAs
facilitates the rational use of mAb conjugates for diagnostic and
therapeutic purposes since it allows for sufficient time for the
antibody–PNA conjugate to nd the target tissue and for the
rapid clearance of the radioactive PNA construct from circula-
tion and normal tissues.
By eliminating the hitherto existing limitations of PNAs such
as insufficient water solubility as well as unfavorable bio-
distribution,41 we successfully optimized this complementary
system for future pretargeting approaches. Nonetheless, the
herein obtained results for our PNA-based approach cannot be
juxtaposed with reported studies applying phosphorodiamidate
morpholino oligomers (MORFs) due to major divergences with
respect to animal models, tumor entities as well as tumor cell-
related molecular targets and corresponding antibodies.
Neglecting these facts, similar tumor uptake and non-target
ratios were achieved.28,31 All in all, as demonstrated in this
article, PNAs are a favorable alternative to MORFs for this eld
of research, especially when considering their relatively facile
synthesis.
More specically, in this article, we initially described the
rst detailed radiopharmaceutical evaluation of PNA bio-
conjugates for tumor pretargeting. We could then demonstrate
that the PEGylation of PNA oligomers resulted into optimized
pharmacokinetic properties. Compared with their non-PEGy-
lated analogue, PEGylated PNAs showed lower kidney and liver
accumulation, better renal excretion and a more benecial
residence time in blood. We also present a versatile conjugation
protocol to modify the EGFR specic therapeutic antibody
cetuximab. Coupling of a cysteine-functionalized PNA oligomer
to the mAb equipped with maleimido functional groups was
achieved at ambient temperature. As expected, under these
conditions, the modication of cetuximab with the PNA
conjugate did not affect its binding properties towards EGFR-
positive tumor cells showing hence that this modied antibody
could be used in our study. Very importantly, in vivo studies in
tumor bearing mice demonstrated the high potential of the
described pretargeting approach. Rapid and efficient in vivo
hybridization of a fast-clearing radiolabeled complementary
PNA with a cetuximab-PNA conjugate led to high specic tumor
accumulation. The studies performed have shown that the 17-
mer PNAs investigated are promising candidates for further
preclinical studies. All in all, this study opens up new avenues
not only in the eld of radioimaging but also in the eld of
cancer radioimmunotherapy. We are currently analyzing if such
an approach could be used to treat cancer by using therapeutic
radionuclides such as 90Y, 177Lu, 186Re or 188Re.
Experimental section
Material and methods
Chemicals and solvents were of reagent grade or better and
purchased from commercial suppliers and were used without
Fig. 5 Biodistribution of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA (24 h post injection of radiotracer) in murine xenograft (NMRI nu/nu mice; A431
tumor cells transplanted into right thigh) 24 h after single administration of (NOTA)3-C225-Cys-c-PNA. Values in the table are averages in SUV
including standard deviation (8 mice).
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further purication unless otherwise specied. Alpha-methoxy-
omega-ethyl-maleimide poly(ethylene glycol) (MeO-PEG-mal;
MeO-PEG2kDa-maleimide with PDI ¼ 1.03; MeO-PEG10kDa-mal-
eimide with PDI ¼ 1.08) and N-alpha-(9-uorenylmethylox-
ycarbonyl)-S-trityl-L-cysteine (Fmoc-L-Cys(Trt)-OH) were
purchased from Iris Biotech. PNA monomers were supplied by
Link technologies. TentaGel S RAM Lys(Boc) Fmoc resin was
purchased from Rapp Polymere. 2,20-dipicolylamine (Dpa-N3)
was prepared following a previously reported procedure.48 All
other chemicals were of reagent-grade and sourced from Sigma-
Aldrich.
ESI-MS spectra were recorded on a Bruker Esquire 6000. The
matrix-assisted laser desorption/ionization time of ight mass
spectrometry (MALDI-TOF) mass spectra were measured on a
Bruker Daltonics Autoex. The experiments were performed in
reector (RP) or linear (LP) mode with positive polarity using a-
cyano-4-hydroxy-cinnamic acid on a Prespotted AnchorChip
(PAC HCCA) or sinapinic acid (SA) as the matrix. LC-MS spectra
were measured on an Acquity™ from Waters system equipped
with a PDA detector and an auto sampler using an Agilent
Zorbax 300SB-C18 analytical column (3.5 mm particle size, 300 Å
pore size, 150  4.6 mm). This LC was coupled to an Esquire
HCT from Bruker (Bremen, Germany) for the MS measure-
ments. The LC run (ow rate: 0.3 mL min1) was performed
with a linear gradient of A (distilled water containing 0.1% v/v
formic acid) and B (acetonitrile (Sigma-Aldrich HPLC-grade),
containing 0.1% v/v formic acid); t¼ 0 min, 5% B; t¼ 3 min, 5%
B; t ¼ 17 min, 100% B; t ¼ 20 min, 100% B; t ¼ 25 min, 5% B.
HPLC purication was performed on a Varian ProStar system
equipped with a UV/Vis spectrometer and an Agilent Zorbax
300SB-C18 prep column (5 mm particle size, 300 Å pore size,
150  21.1 mm. Flow rate: 20 mL min1). The runs were per-
formed with a linear gradient of A (distilled water containing
0.1% v/v TFA) and B (acetonitrile (Sigma-Aldrich HPLC-grade),
containing 0.1% v/v TFA). Preparative run: t ¼ 0 min, 5% B; t ¼
17 min, 42% B; t ¼ 25 min, 100% B; t ¼ 30 min, 100% B; t ¼
32 min, 5% B (for Dpa-PNA, Dpa-Cys-PNA and Cys-c-PNA).
Preparative runs: t ¼ 0 min, 10% B; t ¼ 24 min, 60% B; t ¼
25 min, 100% B; t ¼ 30 min, 100% B; t ¼ 32 min, 10% B (for
Dpa-(Cys-PEGx)-PNA). The size exclusion purication was per-
formed on an AKTAprime Plus system using HiTrap Desalting
5 5 mL GE Healthcare (10 mMHCl in distilled water, ow rate
3 mL min1). Radio-HPLC of the 99mTc labeled Dpa-PNA
derivatives were performed on a Perkin-Elmer system with
quaternary pump (series 200 LC pump) equipped with a radio-
detector (RAMONA from raytest), a UV/Vis-detector (LC 290
from Perkin-Elmer) and an Eurosphere 100 column (5 mm
particle size, 200 mm  4.5 mm, ow rate: 1 mL min1). The
runs were performed with a linear gradient of A (distilled water
containing 0.1% v/v TFA) and B (acetonitrile Fisher HPLC-grade,
containing 0.1% v/v TFA): t ¼ 0 min, 0% B; t ¼ 20 min, 100% B.
Supernatants from samples of arterial blood plasma were
analyzed on a Hewlett Packard system (series 1100) equipped
with a radio-detector (RAMONA from raytest) and a Zorbax C18
300SB column (4 mmparticle size, 9.4 250mm, ow rate: 2 mL
min1, column temperature 30 C). The runs were performed
with a linear gradient of A (50 mM aqueous triethylamine-acetic
acid buffer pH ¼ 6.45) and B (acetonitrile Fisher HPLC-grade): t
¼ 0min, 5% B, t¼ 15min, 50% B, t¼ 16min 95% B, t¼ 20min,
95% B. Radio-TLC of the 64Cu-labeled antibody conjugates
[64Cu]Cu-(NOTA)3-C225 and [
64Cu]Cu-(NOTA)3-C225-Cys-c-PNA
were performed at ITLC-SA plates and 0.9% sodium chloride
solution as mobile phase. UV/Vis measurements and hybrid-
ization studies were performed on a Specord 210 from Analytik
Jena AG. To determine the concentrations of PNA-derivatives
measurements carried out at 260 nm by 90 C with following
extinction coefficients: Cys-c-PNA 3 ¼ 197 mL  nmol1  cm1,
Dpa-PNA, Dpa-(Cys-PEG2kDa)-PNA, and Dpa-(Cys-PEG10kDa)-PNA
3 ¼ 182 mL  nmol1  cm1. Cetuximab derivatives were
measured at 280 nm by room temperature. The extinction
coefficient was determined via UV/Vis calibration curve and
linear regression analysis: C225 3 ¼ 217  14 mL nmol1 cm1.
General chemistry
General procedure for synthesis of PNAs. The synthesis of
the PNAs was performed as previously reported by our groups.48
More specically, the SPPS of PNAs was performed manually in
5 mL polypropylene one-way syringes equipped with a frit at the
bottom. They were lled with 100 mg of polystyrene resin beads
TentaGel S RAM Lys(Boc)Fmoc (0.23 mmol g1). The resin was
swollen in DMF for 1 h before use. All reactions were performed
on a mechanical shaker at 400 rpm with approximately 3–4 mL
of freshly prepared solutions in the syringes. Fmoc/Bhoc-pro-
tected PNA monomers, the Fmoc spacer (5.0 equiv., all from
Link Technologies, Lanarkshire, Scotland) or cysteine were
preactivated in Eppendorf tubes before every coupling step for
2 min with HATU (4.5 equiv.) in DMF, adding DIPEA and 2,6-
lutidine (10.0 equiv. each, 2 min for the T and G(Bhoc) PNA
monomers and the PNA spacer, 5 min for the A(Bhoc)-PNA-
monomer and 7 min for C(Bhoc)-PNA-monomer). For each
coupling step the resin beads were treated with the activated
acid under shaking for 1.5 h and subsequently washed with
DMF. The coupling step was monitored by the Kaiser test. Two
Fmoc deprotection steps were performed with piperidine (20%,
v/v) in DMF (2 + 10 min). The resin beads were then washed
successively with DMF, DCM and DMF. The whole procedure
(deprotection, coupling, monitoring) was repeated for every
PNA monomer until the PNA sequence was completed. Before
cleavage, the resin was shrunk with methanol and dried. The
PNAs were then cleaved using a mixture of triuoroacetic acid–
water–triisopropylsilane 95 : 2.5 : 5 v/v/v [3  1.5 mL (90 min
each)]. The resulting solutions were rst evaporated to dryness
before being precipitated with ice-cold ether. The solids were
centrifuged, washed with ice-cold ether and nally air-dried.
The obtained crude oligomers were lyophilized in acetonitrile–
water, puried and analyzed with RP-HPLC, and nally char-
acterized with ESI and/or MALDI-TOF mass spectrometry.
Cys-c-PNA (H-Cys-spacer-spacer-ataatcacataacataa-Lys-NH2).
To obtain Cys-c-PNA, Fmoc-Cys(Trt)-OH was added to the
growing PNA chain on the beads by using the same protocol as
for PNA monomers (described above). The resulting Cys-c-PNA
was cleaved off the resin following the general protocol shown
above and puried by preparative HPLC to yield white powder.
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Characterization: ESI-MSm/z 852.2 [M + 6H]6+, 730.8 [M + 7H]7+,
639.4 [M + 8H]8+, 568.8 [M + 9H]9+; MALDI-TOF (PAC HCCA, RP)
m/z 5108.2 [M + H]1+, 5130.2 [M + Na]1+.
Dpa-PNA (H-Dpa-spacer-spacer-ttatgttatgtgattat-Lys-NH2). To
append the Dpa ligand to PNA, 4-pentynoic acid was added to
the N-terminus of the PNA sequence according to the procedure
previously reported by Gasser et al.48 Dpa (5 equiv.) and CuI
(2 equiv.) dissolved in a mixture DIPEA–DMF 1 : 6 v/v (4.207 mL)
were introduced into the syringe and the mixture was shaken
overnight. The resin was thoroughly washed by DMF, DCM,
ACN, EDTA 0.1 M, shaken in EDTA 0.1 M for 2 h (3) and
washed by ACN, DCM and DMF. The product was then cleaved
off the resin (see the General procedure above) and isolated by
preparative HPLC as white powder. Characterization: ESI-MS
m/z 1085.2 [M + 5H]5+, 906.6 [M + 6H]6+, 775.5 [M + 7H]7+, 678.7
[M + 8H]8+, 603.4 [M + 9H]9+; 1097.9 [M + Cu+5H]5+, 915.3 [M +
Cu+6H]6+, 785.1 [M + Cu+7H]7+, 686.6 [M + Cu+8H]8+, 610.5 [M +
Cu + 9H]9+; 1066.8 [M  py(CH)2 + 5H]
5+, 889.0 [M  py(CH)2 +
6H]6+, 762.3 [M + –py(CH)2 + 7H]
7+, 667.1 [M + –py(CH)2 + 8H]
8+,
593.1 [M + –py(CH)2 + 9H]
9+. MALDI-TOF (SA, LP) m/z 5422.2
[M + H]1+, 5444.2 [M + Na]1+, 5485.9 [M + Cu + H]1+, 5393.8 [M 
py(CH2) + Cu + H]
1+, 5330.2 [M  py(CH2) + H]
1+.
Dpa-Cys-PNA (H-Dpa-spacer-spacer-Cys-spacer-spacer-ttatgt-
tatgtgattat-Lys-NH2). To allow PEG conjugation via Michael
addition, cysteine residue was added to the PNA sequence as
described above for Cys-PNA. Dpa ligand was introduced as
specied above for DPA-PNA. The product was cleaved off the
resin (see the General procedure) and puried by preparative
HPLC to obtain white powder. Characterization: ESI-MS m/z
831.4 [M + 7H]7+, 727.6 [M + 8H]8+, 647.1 [M + 9H]9+. MALDI-TOF
(SA, LP) m/z 5815.9 [M + H]1+, 5837.8 [M + Na]1+, 5879.4 [M + Cu
+ H]1+, 5787.2 [M  py(CH2) + Cu + H]
1+, 5723.7 [M  py(CH2) +
H]1+, 5745.7 [M  py(CH2) + Na]
1+.
Dpa-(Cys-PEGx)-PNA. Dpa-Cys-PNA and TCEP (10 equiv.) were
dissolved in distilled water (30 mL) and shaken overnight. The
reaction mixture was then lyophilized, redissolved in 10 mM
HCl and separated by size exclusion. The collectedDpa-Cys-PNA
fractions were combined and split into two asks (20 mL
each). MeO-PEG2kDa-maleimide (5 equiv.) or MeO-PEG10kDa-
Maleimide (5 equiv.) was added and the mixture was then
shaken overnight. The reaction mixtures were lyophilized,
puried and analyzed with RP-HPLC and characterized by ESI
and MALDI-TOF mass spectrometry.
Characterization of Dpa-(Cys-PEG2kDa)-PNA. MALDI-TOF
(PAC HCCA, LP): a Gaussian distribution of peaks correspond-
ing to PEG of various lengths (PEG35 to PEG45) was observed;
some of the most intense peaks: Dpa-PEG42-PNA m/z 7822.2
[M + H]1+, Dpa-PEG43-PNAm/z 7866.2 [M + H]
1+, Dpa-PEG44-PNA
m/z 7910.2 [M + H]1+, Dpa-PEG45-PNAm/z 7954.4 [M + H]
1+, Dpa-
PEG46-PNA m/z 7998.4 [M + H]
1+, Dpa-PEG47-PNA m/z 8042.5
[M + H]1+, Dpa-PEG41-PNAm/z 7778.1 [M + H]
1+, Dpa-PEG40-PNA
m/z 7734.0 [M + H]1+, Dpa-PEG39-PNAm/z 7690.0 [M + H]
1+, Dpa-
PEG38-PNA m/z 7645.9 [M + H]
1+, Dpa-PEG37-PNA m/z 7601.9
[M + H]1+. Corresponding [M + 2H]2+ states, such as m/z 3911.6
(Dpa-PEG42-PNA) were also observed.
Characterization of Dpa-(Cys-PEG10kDa)-PNA. MALDI-TOF
(PACHCCA, LP) a Gaussian distribution of peaks corresponding
to PEG of various lengths (PEG230 to PEG270) was observed;
some of most intense peaks: Dpa-PEG241-PNA m/z 16 588.1 [M +
H]1+, Dpa-PEG242-PNA m/z 16 632.2 [M + H]
1+, Dpa-PEG243-PNA
m/z 16 676.2 [M + H]1+, Dpa-PEG244-PNA m/z 16 720.3 [M + H]
1+,
Dpa-PEG245-PNA m/z 16 764.3 [M + H]
1+, Dpa-PEG246-PNA m/z
16 808.4 [M + H]1+, Dpa-PEG247-PNA m/z 16 852.4 [M + H]
1+,
Dpa-PEG248-PNA m/z 16 896.5 [M + H]
1+, Dpa-PEG249-PNA m/z
16 940.1 [M + H]1+, Dpa-PEG250-PNA m/z 16 984.6 [M + H]
1+,
Dpa-PEG251-PNA m/z 17 028.6 [M + H]
1+, Dpa-PEG252-PNA m/z
17 072.7 [M + H]1+, Dpa-PEG253-PNA m/z 17 116.7 [M + H]
1+,
Dpa-PEG254-PNA m/z 17 160.8 [M + H]
1+, Dpa-PEG255-PNA m/z
17 204.8 [M + H]1+, Dpa-PEG256-PNA m/z 17 248.9 [M + H]
1+,
Dpa-PEG257-PNA m/z 17 292.9 [M + H]
1+, Dpa-PEG258-PNA m/z
17 336.9 [M + H]1+, Dpa-PEG259-PNA m/z 17 381.0 [M + H]
1+,
Dpa-PEG260-PNA m/z 17 425.1 [M + H]
1+. Corresponding [M +
2H]2+ states, such as m/z 8382.7 (Dpa-PEG245-PNA) were also
observed.
Polydispersity index (PDI) calculation for PEGylated PNAs. PDI
index was calculated using the following formula:
PDI ¼ Mw/Mn

















where Mi is mass of a polymer of a certain length and Ni is the
amount of this polymer present.
Mn and Mw were estimated from MALDI spectra. As PEG
polymers used for synthesis had PDI <1.1 and PNA was mono-
disperse, PDI of PEGylated PNAs was expected to be <1.1.
Therefore, no mass discrimination effect should have inter-
fered, so Ni was assumed to be proportional to peak intensity in
MALDI spectra. Calculated PDIs corresponded to those of PEG
starting material.
Bioconjugation chemistry
(NOTA)3-C225. 3 mL of Erbitux® stock solution (5 mg mL
1)
for infusion purposes were added to a Jumbosep™ centrifugal
devices (30 kDa cut-off) containing 55 mL of 50 mM sodium
bicarbonate saline buffer (pH 6.4). In order to completely
remove infusion solution by sodium bicarbonate saline buffer,
the procedure of centrifugal ltration was carried out 6 times
(2500 min1, 60 min, 10 C). The resulting Erbitux® solution
(6 mL) was nally concentrated to circa 1.2 mL by application
of Macrosep™ Advance centrifugal device (30 kDa cut-off;
2500 min1, 90 min, 10 C). The concentrated Erbitux® solution
was transferred into a Teon-coated plastic vial and 10.2 mg of
p-SCN-Bn-NOTA  3HCl (18.2 mmol) dissolved in 2.130 mL
50 mM HEPES buffer (pH 7.2) were added in aliquots. The
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5601–5616 | 5611






















































































































molar ration of the NOTA derivative to Erbitux® was 185 : 1 with
a resulting pH value of 6.9. The reaction mixture was le for 22
h at room temperature and the vial was swirled occasionally.
The reaction mixture was worked up by centrifugal ltration
for 6 times (Jumbosep™ centrifugal devices; 30 kDa cut-off;
50 mM sodium bicarbonate saline buffer; pH 6.4; 2500 min1,
60 min, 10 C). Finally, the product solution was further
concentrated to circa 1.0 mL by Macrosep™ Advance centrif-
ugal device (30 kDa cut-off; 2500 min1, 90 min, 10 C). The
recovery of the antibody was almost quantitatively (98% by
UV/Vis measurement). This value was assumed as yield. MALDI-
TOF (SA, LP): Gaussian distribution of peaks was observed;
most intense peaks: m/z 154 106 [M + H]1+, m/z 77 184 [M +
2H]2+.
(NOTA)3-C225-mal. A solution of 50 mM sodium bicarbonate
saline (pH 6.4; 0.9% w/w NaCl) containing (NOTA)3-C225 (app.
95–100 nmol) was diluted with phosphate buffer (pH 6.2) to a
nal volume of 3.400 mL and 1000 nmol 4-maleimido-butyric
acid N-succinimidyl ester (0.28 mg) in 50 mL DMSO were added.
The reaction mixture was le for 5 h at room temperature and
swirled occasionally. The resulting (NOTA)3-C225-mal was
subsequently puried by centrifugal ltration for 6 times
(Jumbosep™ centrifugal devices; 30 kDa cut-off; phosphate
buffer pH 6.4; 2500 min1, 60 min, 10 C). Finally, the product
solution was further concentrated to circa 2.0 mL by Macro-
sep™ Advance centrifugal device (30 kDa cut-off; 2500 min1,
160 min, 10 C). The recovery of the antibody was 85% (UV/Vis
measurement). This value was assumed as yield. MALDI-TOF
(SA, LP): Gaussian distribution of peaks was observed; most
intense peaks: m/z 155 477 [M + H]1+, m/z 77 984 [M + 2H]2+.
(NOTA)3-C225-Cys-c-PNA. 960 nmol of Cys-c-PNA (5110 g
mol1) were dissolved in a mixture of 1000 mL of phosphate
buffer and 1000 mL DMSO. This solution was added in aliquots
to a Teon-coated plastic vial containing the previously
concentrated 2 mL phosphate buffer of (NOTA)3-C225-mal. The
molar ratio of Cys-c-PNA derivative to (NOTA)3-C225-mal was
app. 11 : 1. The reaction mixture was le for 4 days at room
temperature and the vial was swirled occasionally. The high
viscosity of DMSO containing solution led to extraordinary slow
centrifugal ltration (Macrosep™ Advance device, 30 kDa cut-
off). The addition of 12 mL phosphate buffer was required to
dilute the reaction mixture, which also led to precipitation of
non-reacted Cys-c-PNA. Subsequently, the solution was trans-
ferred into several Protein low-bind tubes from Eppendorf,
cooled to 10 C for 2 h, and centrifuged for 60 min (2500 min1,
10 C). The resulting clear supernatant was transferred carefully
into a Jumbosep™ device. Aer adding 40 mL of phosphate
buffer the diluted reaction mixture was puried by centrifugal
ltration. The purication using Jumbosep™ devices was per-
formed 6 times. Finally, the product solution was further
concentrated to circa 1.0 mL by Macrosep™ Advance centrif-
ugal device (30 kDa cut-off; 2500 min1, 90 min, 10 C). MALDI-
TOF (SA, LP): Gaussian distribution of peaks was observed;
most intense peaks: m/z 168 614.1 [M + H]1+, m/z 86 022 [M +
2H]2+.
The number of bound Cys-c-PNA to cetuximab was also
spectrophotometrically determined by measuring the
absorbance at different wavelengths.92–94 The maximum absor-
bance of cetuximab was found to be at 280 nm and of Cys-c-PNA
at 260 nm. Assuming that the conjugation of Cys-c-PNA to
cetuximab will not inuence the extinction coefficients of the
individual compounds Lambert–Beer law were formulated at
260 nm and 280 nm. The extinction coefficients of cetuximab
and Cys-c-PNA were determined via UV/Vis calibration curves
and linear regression analysis: 3cetuximab 280 nm ¼ 217  14
mL nmol1 cm1, 3cetuximab 260 nm ¼ 97  6 mL nmol
1 cm1,
3Cys-c-PNA 280 nm¼ 114 4 mL nmol
1 cm1 and 3Cys-c-PNA 260 nm¼
192  6 mL nmol1 cm1. Based on the 260 nm/280 nm absor-
bance ratio, the conjugation degree can be calculated with
following equation:
n ¼
E280 nm  3C225 260 nm  E260 nm  3C225 280 nm
E260 nm  3Cys-c-PNA 280 nm  E280 nm  3Cys-c-PNA 260 nm
Radiochemistry
99mTc-labeling. 1.5–2.5 mL of freshly eluted [99mTc]TcO4

solution (400–1450 MBq) were injected into IsoLink® vial. The
resulting mixture was heated to 100 C for 30 min. In order to
prevent pressure issues and to concentrate the resulting [99mTc]
Tc(CO)3(H2O)3
+ solution, a syringe needle was inserted through
the rubber plug of the vial. The needle was removed before the
mixture was cooled to room temperature.
For each radiolabeling experiment 10 nmol of particular
Dpa-PNA derivative from stock solution diluted in 400 mL of
phosphate buffer (pH 5.4) were used. The labeling tube con-
taining the PNA solution was gently ushed with argon for
5 min. Subsequently, approximately 400 mL [99mTc]Tc(CO)3(H2-
O)3
+ kit solution (250–580MBq) were added. The pH value of the
radiolabeling mixture was tested by a triple zone pH-paper
(Tritest pH 1–11). Optimal pH for radiolabeling ranges from 7 to
8. Occasionally, the pH value had to be adjusted by addition of
further phosphate buffer (pH 5.4 or 8.2). The mixture was
heated to 70 C for 40 min and cooled to room temperature. The
radiochemical yield (rcy) was determined by radio-HPLC. For
HPLC injection purposes, 10 mL of labeling mixture were added
to 90 mL of HPLC solvent A. For all radiolabeling experiments rcy
of >95% determined from reaction mixtures (n ¼ 19) were
obtained. Decay corrected effective specic activities of up to
58 GBq mmol1 were achieved. For in vivo studies (bio-
distribution and SPECT imaging) the radiolabeling mixtures
were concentrated and re-buffered (sterile PBS) by centrifugal
ltration (13 200 min1; 20 min; 25 C; recovery of activity 70–
80%). Centrifugal ltration was applied for purication
purposes, if insufficient rcy (<95%) occurred. A typical volume
of radiolabeled Dpa-PNA derivatives was 150–250 mL sterile
phosphate buffered saline (PBS). Characterization: Radio-HPLC
tR:
99mTcO4
 3.0 min; [99mTc(H2O)3(CO)3]
+ 5.0–6.0 min; Dpa-
PNA 10.5 min; Dpa-(Cys-PEG2kDa)-PNA 12.0 min; Dpa-(Cys-
PEG10kDa)-PNA 12.9 min.
64Cu-labeling. 3 nmol of antibody stock solution of (NOTA)3-
C225 and (NOTA)3-C225-Cys-c-PNA, resp., were diluted in
200 mL MES buffer (1 M, pH ¼ 6.0). 50 MBq aliquots of [64Cu]
5612 | Chem. Sci., 2015, 6, 5601–5616 This journal is © The Royal Society of Chemistry 2015






















































































































CuCl2 dissolved in 0.01 M HCl were added to 200 mL MES buffer
(1 M, pH ¼ 6.0) and then mixed with the antibody solution. The
reaction mixture was incubated in a thermomixer for 35 min at
30 C and the vial was swirled occasionally by manual stimu-
lation. Aerwards, 4 mL of an aqueous EDTA solution (0.75 mM)
were added to remove non-specic bound 64Cu. Aer a reaction
time of 10 min at room temperature the product mixture was
checked by radio TLC for complete complexation of [64Cu]Cu2+.
Rcy of >99% were achieved without any further purication
(radiochemical purity >99%). [64Cu]Cu-(NOTA)3-C225 and
[64Cu]Cu-(NOTA)3-C225-Cys-c-PNA could be labeled with effec-
tive specic activities of up to 16.6 GBq mmol1. Characteriza-
tion: Radio-TLC [64Cu]Cu-(NOTA)3-C225 Rf ¼ 0, [
64Cu]Cu-
(NOTA)3-C225-Cys-c-PNA Rf ¼ 0.
Hybridization studies
Self-complementarity. UV/Vis cuvettes were lled with
particular PNA probe at room temperature. Aer cooling to 5 C
the samples were heated to 95 C.
Melting curves (n ¼ 2). For hybridization studies equimolar
amounts of 3 mM stock solutions of each Dpa-PNA derivatives
and complementary Cys-c-PNA were lled into the cuvette. For
the rst step the single probes were heated up to 95 C for 5 min
to induce complete de-hybridization. The second step included
cooling to 5 C to achieve a fully hybridization with a gradient of
2 C min1. During the third step the samples were heated with
a gradient of 2 C min1 from 5 C to 95 C. The data points
were analyzed with a polynomial t (9th order) by the analysis
soware Origin Pro 8.6. The melting point TM is equal to the
maximum of the 1st differentiation of the sigmoid shaped
melting curve.
Biological studies
Determination of log Do/w at 25  1
C. Information on the
lipophilicity of 99mTc-labeled Dpa-PNA, Dpa-(Cys-PEG2kDa)-PNA
and Dpa-(Cys-PEG10kDa)-PNA was obtained by distribution
experiments in a water/1-octanol system. All radiolabeled PNA
derivatives were isolated by HPLC in radiochemical purity of
>98%. Aliquots of 250 kBq were added to phosphate buffered
saline with pH values of 7.2, 7.4 and 7.6 reaching a total volume
of 500 mL in 2 mL microcentrifuge tubes. To this solution,
500 mL of 1-octanol were added and the two phases were
agitated in a thermomixer for 30 min at (25  1) C. Aer
centrifugation of samples, aqueous and organic phases were
separated and aliquots of both phases were measured using an
automated gamma counter (PerkinElmer Life and Analytical
Sciences). Each value was recorded as triplet.
Cell culture. For binding studies, two different adherent
human tumor cell lines were used: the epidermoid carcinoma
cell line A431 (ATCC® Number: CRL-1555) and the squamous
cell carcinoma cell line FaDu (ATCC® number: HTB-43). All
cells were cultured as previously reported.87,103
Binding affinity of [64Cu]Cu-(NOTA)3-C225-Cys-c-PNA and
[64Cu]Cu-(NOTA)3-C225 to human EGFR-presenting cells. In
vitro binding studies of [64Cu]Cu-(NOTA)3-C225-Cys-c-PNA and
[64Cu]Cu-(NOTA)3-C225 were performed as previously reported
by Zarschler et al.103 with slight modications. Briey, cells were
plated in 24 well cell culture microplates (Greiner Bio-One) at a
density of 1  105 cells per 0.5 mL per well and incubated for
48 h prior to addition of radiolabeled cetuximab conjugates.
Aer 48 h, cells were preincubated for 30 min at 4 C before the
addition of different concentrations of radiolabeled cetuximab
conjugates ranging from 0.1 nM to 100 nM. The cell culture
microplates were further incubated for 60 min at 4 C.
Following treatment with radiolabeled cetuximab conjugates,
cells were washed three times with PBS in order to ensure
removal of loosely attached proteins from the cellular
membrane. Finally, cell lysis was achieved by the addition of 1%
SDS/0.1 M NaOH and incubation for 30 min at room tempera-
ture with vigorous shaking. The radioactivity in the cell extracts
was quantied using an automated gamma counter (Perki-
nElmer Life and Analytical Sciences). Total protein concentra-
tion in cell extracts was determined colorimetrically with the DC
Protein Assay (Bio-Rad Laboratories) according to the manu-
facture's microplate assay protocol using bovine serum albumin
as protein standard.
Animal husbandry. The local animal research committee at
the Landesdirektion Dresden approved the animal facilities and
the experiments according to institutional guidelines and the
German animal welfare regulations. Wistar rats (Wistar Uni-
lever, HsdCpb: Wu, Harlan Winkelmann GmbH, Borchen,
Germany) and mice (NMRI, nu/nu) were housed at 26  2 C.
The received standard food and tap water ad libitum.
Biodistribution studies in Wistar rats and tumor mice.
Wistar rats with a mean body weight 124  25 g of 55 animals
and female NMRI nu/nu tumor mice with a body weight 32 
2.5 g of 8 animals were used. Animals were anesthetized with
desuran (Suprane, Baxter, Unterschleibheim, Germany)
initially with 10% in a 30% oxygen air mixture. The radiotracer
(333  66 kBq in 0.5 mL) was injected into a lateral tail vein and
the animals were recovered. The injected dose was calculated
from the activities of the syringes before and aer the injection.
Aer 5 and 60 min for rats and 24 h for tumor mice, animals
were sacriced under anesthesia. Blood was obtained by heart
puncture and the organs and tissues of interest were removed
and weighed and the radioactivity was determined using an
automated NaI (Tl) well counter Wallac 1470 Wizard (Perkin
Elmer Lifescience). The percentage of injected dose of organ (%
ID) was calculated for organs that could be completely extracted
and the standardized uptake value (SUV) was calculated
according
SUV ¼
tissue activity body weight
injected activity tissue weight
(1)
The activity amounts in the urine were calculated as differ-
ence between the injected dose and the recovery from all indi-
vidual organs, tissues, blood and carcass.
Metabolic proling. To evaluate the kinetics andmetabolism
of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA in arterial rat blood, rats
were anesthetized with desuran and a catheter was set into the
right femuralis. Aer radiotracer i.v. injection in a lateral tail
vein were samples of arterial blood withdrawn and the blood
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 5601–5616 | 5613






















































































































plasma was analyzed for [99mTc](Tc-Dpa)-(Cys-PEG–10kDa)-PNA
content by radio-HPLC. The corresponding supernatants were
analyzed by radio-HPLC.
SPECT of Wistar rats and tumor mice in pretargeting trial.
Wistar rats (body weight 140  51 g) were under desuran
anesthesia injected in a lateral tail vein with [99mTc](Tc-Dpa)-
(Cys-PEG10kDa)-PNA (58 MBq) and recovered. Aer one hour
were the rats anesthetized, in the imaging bed positioned and
in the NanoScanSPECT/CT imaged. CT was carried out in the
NanoScan PET/CT. The DICOM image volume data were pro-
cessed with InterView (Mediso, Budapest, Hungary) or con-
verted to Siemens ECAT7 format for further processing with
Rover soware (ROI Visualization, Evaluation and Image
Registration, ABX Radeberg, Germany). A431 human squamous
carcinoma cells (Sigma Aldrich, 85090402-1VL) were subcuta-
neously inoculated in female NMRI nu/nu mice. 2  106 cells in
100 mL PBS were subcutaneously injected in the right thigh.
Mice were studied when the tumors reached a size of 8 and
13 mm. The mice with A431 tumors were intravenously injected
with 4 nmol (NOTA)3-C225-Cys-c-PNA. At the next day, 45 MBq
of [99mTc](Tc-Dpa)-(Cys-PEG10kDa)-PNA were intravenously
injected and imaged 1 h and 20 h later using NanoScan SPECT.
CT was carried out in NanoScan PET/CT. The image processing
was carried out as described above.
Statistics. The calculations and statistics were carried out
with InterView (Mediso, Hungary), ROVER (ABX GmbH. Ger-
many), R (A language and environment for statistical
computing, R Foundation for Statistical Computing, Vienna,
Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.)
and GraphPad Prism version 5.00 for Windows (GraphPad
Soware, San Diego California USA, http://www.graphpad.com).
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48 G. Gasser, K. Jäger, M. Zenker, R. Bergmann, J. Steinbach,
H. Stephan and N. Metzler-Nolte, J. Inorg. Biochem., 2010,
104, 1133–1140.
49 F. Chang, T. Qu, M. Rusckowski and D. J. Hnatowich, Appl.
Radiat. Isot., 1999, 50, 723–732.
50 I. Eke, M. Ingargiola, C. Förster, L. A. Kunz-Schughart,
M. Baumann, R. Runge, R. Freudenberg, J. Kotzerke,
J. M. Heldt, H. J. Pietzsch, J. Steinbach and N. Cordes, Int.
J. Radiat. Biol., 2014, 90, 678–686.
51 M. Ingargiola, R. Runge, J. M. Heldt, R. Freudenberg,
J. Steinbach, N. Cordes, M. Baumann, J. Kotzerke,
G. Brockhoff and L. A. Kunz-Schughart, Int. J. Cancer,
2014, 135, 968–980.
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